Zobrazeno 31 - 40
of 250
pro vyhledávání: ''
Autor:
Bram Boecks, Bruce A. Littlefield, Amy Weaver, Elodie Modave, Patrick Schöffski, Agnieszka Wozniak, Diether Lambrechts
Publikováno v:
Cancer Research. 80:4280-4280
Background. The recent randomized phase 3 trial Eisai Study 309 evaluated efficacy of eribulin (ERI) compared to dacarbazine (DTIC) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS). Improved overall survival (OS) in ERI-treated patients led to
Autor:
Reuben Kapur, Silvia Marino, Scott H. Boswell, D. Roodman, Larry D. Cripe, Santosh Kumar Pasupuleti, Lakshmi Reddy Palam, Hamid Sayar, Sravanti Rangaraju, Daniela N. Petrusca, Heiko Konig, Bhaskar Ramdas, Katie J. Sargent
Publikováno v:
Cancer Research. 80:800-800
FLT3 mutations (mFLT3) in acute myeloid leukemia (AML) carry a poor prognosis.The mandatory co-occurrence of other driver mutations with mFLT3 leads to suboptimal clinical responses with single agent FLT3 inhibitors (FLT3i). Pre-existing or emergent
Autor:
Yong J. Lee
Publikováno v:
Cancer Research. 80:1239-1239
Ferroptosis has been reported as a unique form of cell death. However, in recent years, researchers have increasingly challenged the uniqueness of ferroptosis compared to other types of cell death. In this study, we examined whether ferroptosis share
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Publikováno v:
Cancer Research. 80:4038-4038
Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum, and the current treatment mainly relies on chemotherapies. For example, ERBITUX® /cetuximab is an FDA approved targetedtherapy drug to treat CRC with wild-type KRAS, the 11%
Autor:
Andrew J. Dropsey, Jason Manro, Sheng-Bin Peng, Melinda D. Willard, Weihua Shen, Sajan Joseph, Eunice Yuen, Shripad V. Bhagwat, Baohui Zhao, Denis J. McCann, Shufen Cai, William T. McMillen, Lisa Kindler
Publikováno v:
Cancer Research. 80:5225-5225
The combination of BRAF and MEK inhibitors have been clinically studied, and three different combinations (dabrafenib plus trametinib, vemurafenib plus cobimetinib and encorafenib plus binimetinib) are approved by the FDA for treatment of melanoma pa
Autor:
Tara N. Fujimoto, Meifang Yu, Yanqing Huang, Nicholas D. Nguyen, Cullen M. Taniguchi, Abagail M. Delahoussaye, Manuel A. Estrada
Publikováno v:
Cancer Research. 80:555-555
Background: Pancreatic ductal adenocarcinoma (PDAC) is driven by activating Kras mutations which cause a fragmented mitochondrial phenotype. We recently demonstrated that leflunomide, an FDA-approved drug for rheumatoid arthritis, could be repurposed
Autor:
Cari Nicholas, Vineeth Sukrithan, Joseph Locker, Hongling Zhao, Juntao Zou, Edward L. Schwartz, Yingjiao Xue, Liang Zhu, Niloy J. Iqbal
Publikováno v:
Cancer Research. 80:1060-1060
The identification of driver mutations and their corresponding targeted drugs has led to significant improvements in the treatment of non-small cell lung cancer (NSCLC) and other solid tumors; however, similar advances have not been made in the treat
Publikováno v:
Cancer Research. 80:5027-5027
Head and neck cancer (HNC) is the sixth leading cause of cancer in the world, and the third most common neoplasia in developing countries [1]. Patients with HNC may suffer significant pain, for which opioids are commonly given. However, recent report
Publikováno v:
Cancer Prevention Research. 13:A46-A46
Purpose: We previously showed diet-induced obesity (DIO) increases (and calorie restriction decreases) systemic markers of inflammation and azoxymethane (AOM)-induced colon carcinogenesis in FVB/N mice. Our current study examines whether moderate wei